Immupharma PLC Lupuzor Pivotal Phase III Study Update (6822I)

TIDMIMM

RNS Number : 6822I

Immupharma PLC

23 March 2018

23 March 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

Lupuzor(TM) Pivotal Phase III Study Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor(TM) pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018.

Lupuzor(TM) is the Company's lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.

Commenting on the trial update, Tim McCarthy, Chairman, said: "With the continued robust safety record of Lupuzor(TM) achieved over this trial, we look forward with confidence to reporting top line results in the near future."

For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 
 For further information please 
  contact: 
                                             + 44 (0) 20 
   ImmuPharma plc (www.immupharma.com)         7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                              + 44 (0) 7721 
    Twitter: @immupharma                          413496 
 
   Northland Capital Partners Limited 
    David Hignell, Dugald Carlean, 
    Jamie Spotswood, Corporate Finance    [phone] 
    Rob Rees, Corporate Broking                     6625 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFKBDDCBKDNNB

(END) Dow Jones Newswires

March 23, 2018 03:00 ET (07:00 GMT)